Elevation Oncology Inc (ELEV)

Currency in USD
0.365
-0.008(-2.15%)
Closed·
Showing Elevation Oncology historical data. For real-time data please try another search
Fair Value
Day's Range
0.3530.379
52 wk Range
0.2213.090
Key Statistics
Prev. Close
0.365
Open
0.374
Day's Range
0.353-0.379
52 wk Range
0.221-3.09
Volume
4.82M
Average Volume (3m)
1.35M
1-Year Change
-53.22%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELEV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Elevation Oncology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Elevation Oncology Inc Company Profile

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It’s lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors. It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. As of July 23, 2025, Elevation Oncology, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Elevation Oncology Inc SWOT Analysis


Promising ADC Pipeline
Elevation Oncology's lead candidate EO-3021 shows best-in-class efficacy for gastric cancers, with a 43% objective response rate in Claudin-selected patients
Safety Advantage
EO-3021's favorable safety profile, particularly the absence of significant hematological adverse events, positions it well for potential combination therapies
Strategic Combinations
Explore Elevation's innovative approach to combining EO-3021 with existing treatments, potentially expanding its market reach in first and second-line settings
Financial Outlook
With a $111M cash balance and analyst price targets ranging from $6 to $7, Elevation Oncology is positioned to fund operations through key clinical milestones into 2026
Read full SWOT analysis

Compare ELEV to Peers and Sector

Metrics to compare
ELEV
Peers
Sector
Relationship
P/E Ratio
−0.5x0.0x−0.5x
PEG Ratio
−0.040.000.00
Price/Book
0.5x0.0x2.6x
Price / LTM Sales
-0.0x3.3x
Upside (Analyst Target)
−1.4%0.0%43.5%
Fair Value Upside
Unlock0.0%6.9%Unlock

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-- / -0.2213
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ELEV Income Statement

People Also Watch

9.590
UMAC
-3.23%
7.720
AMPX
-2.28%
259.78
AVAV
-1.26%
6.9500
IMNN
-2.71%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.